MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC)

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Safety Study ◽

Locally Recurrent ◽

2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70885-6 ◽

2007 ◽

Vol 5 (4) ◽

pp. 221 ◽

Cited By ~ 1

Author(s):

I.E. Smith ◽

L. Biganzoli ◽

H. Cortes-Funes ◽

F. Franke ◽

Y. Mostafa Kamel ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Safety Study ◽

Locally Recurrent ◽

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

European Journal of Cancer ◽

10.1016/j.ejca.2014.10.008 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3077-3088 ◽

Cited By ~ 16

Author(s):

S.W. Lam ◽

S.M. de Groot ◽

A.H. Honkoop ◽

A. Jager ◽

A.J. ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Locally Recurrent ◽

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70439-5 ◽

2014 ◽

Vol 15 (11) ◽

pp. 1269-1278 ◽

Cited By ~ 82

Author(s):

Gunter von Minckwitz ◽

Fabio Puglisi ◽

Javier Cortes ◽

Eduard Vrdoljak ◽

Norbert Marschner ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Locally Recurrent ◽

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

OncoTargets and Therapy ◽

10.2147/ott.s103954 ◽

2016 ◽

Vol Volume 9 ◽

pp. 3771-3781 ◽

Cited By ~ 3

Author(s):

Xiao-Qun Liu ◽

Xiangdong Liu ◽

Tiankui Qiao ◽

Wei Chen ◽

Sujuan Yuan

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Controlled Trials ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Randomized Controlled ◽

Locally Recurrent ◽

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

BMC Cancer ◽

10.1186/1471-2407-13-164 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 15

Author(s):

Lucia Del Mastro ◽

Alessandra Fabi ◽

Mauro Mansutti ◽

Michele De Laurentiis ◽

Antonio Durando ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Trial ◽

Open label, comparative, randomised, multicentre study of trastuzumab given with docetaxel versus sequential single agent therapy with trastuzumab followed by docetaxel as first-line treatment for Her2neu+++ metastatic breast cancer patients

http://isrctn.org/> ◽

10.1186/isrctn13770586 ◽

2012 ◽

Author(s):

J.G.M. Klijn

Keyword(s):

Breast Cancer ◽

Single Agent ◽

Metastatic Breast ◽

Line Treatment ◽

Breast Cancer Patients ◽

First Line ◽

Open Label ◽

Single Agent Therapy ◽

Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2012.07.004 ◽

2012 ◽

Vol 12 (5) ◽

pp. 322-330 ◽

Cited By ~ 5

Author(s):

Rachel Borson ◽

Graydon Harker ◽

James Reeves ◽

Thaddeus Beck ◽

Steven Hager ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Locally Recurrent ◽

Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC): Interim safety analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1148 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1148-1148

Author(s):

R. Borson ◽

W. G. Harker ◽

J. E. Reeves ◽

J. Bromund ◽

L. Zhao ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Safety Analysis ◽

Line Treatment ◽

First Line ◽

Locally Recurrent ◽

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.635 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 635-635

Author(s):

Shannon Puhalla ◽

Sharon Wilks ◽

Adam Brufsky ◽

Joyce O'Shaughnessy ◽

Lee Steven Schwartzberg ◽

...

Keyword(s):

Breast Cancer ◽

Multicenter Study ◽

Metastatic Breast ◽

Clinical Effects ◽

Line Treatment ◽

First Line ◽

Eribulin Mesylate ◽

Locally Recurrent ◽